1 Development and Performance Assessment of a Novel Plasma p-Tau181 Assay

2 Reflecting Tau Tangle Pathology in Alzheimer's Disease

3

4 AUTHORS/AFFILIATIONS:

- 5 Kenji Tagai^{1,2,7}, Harutsugu Tatebe^{1,7}, Sayo Matsuura¹, Zhang Hong¹, Naomi Kokubo¹,
- 6 Kiwamu Matsuoka¹, Hironobu Endo¹, Asaka Oyama¹, Kosei Hirata¹, Hitoshi Shinotoh¹,
- 7 Yuko Kataoka¹, Hideki Matsumoto^{1,3}, Masaki Oya¹, Shin Kurose^{1,4}, Keisuke Takahata^{1,4},
- 8 Masanori Ichihashi¹, Manabu Kubota¹, Chie Seki¹, Hitoshi Shimada^{1,5}, Yuhei Takado¹,
- 9 Kazunori Kawamura¹, Ming-Rong Zhang¹, Yoshiyuki Soeda⁶, Akihiko Takashima⁵,
- 10 Makoto Higuchi¹, Takahiko Tokuda^{1*}
- 11
- ¹² ¹ Institute for Quantum Medical Science, Quantum Life and Medical Science
- 13 Directorate, National Institutes for Quantum Science and Technology, Chiba 263-8555,
- 14 Japan
- ¹⁵ ² Department of Psychiatry, The Jikei University of Medicine, Tokyo 105-8461, Japan
- ³ Department of Oral and Maxillofacial Radiology, Tokyo Dental College, Tokyo
- 17 101-0061, Japan
- ⁴ Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016,
- 19 Japan
- ⁵ Department of Functional Neurology & Neurosurgery, Center for Integrated Human
- Brain Science, Brain Research Institute, Niigata University, Niigata 951-8585, Japan
- ⁶ Laboratory for Alzheimer's Disease, Department of Life Science, Faculty of Science,
- 23 Gakushuin University, Tokyo 171-8588, Japan
- ²⁴ ⁷ These authors contributed equally
- ^{*}Correspondence: tokuda.takahiko@qst.go.jp
- 26
- 27

1	Abstract: Several blood-base	d assays for phosphorylated tau (p-tau) have been

- 2 developed to detect brain tau pathologies in Alzheimer's disease (AD). However, plasma
- 3 p-tau measured by currently available assays is influenced by brain amyloid and,
- 4 therefore, could not accurately reflect brain tau deposits. Here, we devised a novel
- 5 immunoassay that can quantify N- and C-terminally truncated p-tau fragments
- 6 (mid-p-tau181) in human plasma. We measured plasma p-tau181 levels in 164
- 7 participants who underwent both amyloid and tau positron emission tomography (PET)
- 8 scans using mid-p-tau181 and conventional p-tau181 assays. The mid-p-tau181 assay
- 9 displayed stronger correlations with tau PET accumulation than the conventional assay
- 10 in the AD continuum and accurately distinguished between tau PET-positive and
- 11 -negative cases. Furthermore, the mid-p-tau181 assay demonstrated a trajectory similar
- 12 to tau PET alongside cognitive decline. Consequently, our mid-p-tau181 assay could be
- 13 useful in evaluating the extent of brain tau burden in AD.
- 14

15 Keywords: Plasma biomarker, Tau phosphorylated at threonine 181 (p-tau181), Simoa,

- 16 Tau PET, Alzheimer's disease
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 29 6 -
- 3031
- 32
- 33
- 34
- 35
- 36

1 Introduction

 $\mathbf{2}$ Estimates project that the number of people with dementia worldwide will reach 153 million by 2050^1 , highlighting the urgent need to address the remarkable health and 3 4 social impacts of this condition. Alzheimer's disease (AD), the most prevalent form of dementia, has been characterized as the deposit of two abnormal proteins, namely 5amyloid- β (A β) and tau, in the brain. Over the years, numerous disease-modifying 6 therapies (DMTs) targeting these abnormal proteins have been developed², with the $\overline{7}$ 8 Food and Drug Administration (FDA) having recently approved several DMTs targeting A β due to their efficacy in decreasing brain amyloid deposition and modestly slowing 9 AD progression³⁻⁵. Researchers anticipate that these DMTs will be increasingly utilized 10 in clinical practice, with the potential for developing additional DMTs targeting not only 11 12A β but also tau in the near future⁶. Biomarkers have become an integral part of clinical trials on DMTs given their 13widespread use for subject recruitment and outcome measurements². The 14amyloid/tau/neurodegeneration (A/T/N) biomarker classification system had been 15proposed for the biological staging of AD^7 . In particular, positron emission tomography 16(PET) has emerged as a well-established imaging biomarker for assessing the 17accumulation of A β and tau in the brain⁸, playing a critical role in evaluating novel 18 DMTs^{4,9}. The noteworthy decline in amyloid accumulation based on PET findings¹⁰ 19 may have expedited the FDA approval of aducanumab². Moreover, incorporating tau 20PET as a screening measure, assuming that high tau accumulation may cause resistance 21to anti-amyloid therapy, may have played a part in the success of the donanemab 22clinical trial^{4,11}. Despite their usefulness, PET scans are not ideal for frequent 2324assessment or large-scale screening given their limited availability, high cost, and radiation exposure¹². Similarly, A β and p-tau in the cerebrospinal fluid (CSF) have also 25been accepted as standard biomarkers for qualifying AD pathology^{13,14}. However, CSF 26testing has seen somewhat limited use considering its invasiveness, low-throughput 27nature, and need for expertise during CSF sampling^{12,15}. Based on the present 2829circumstances surrounding the development of biomarkers for AD, one of the most critical unmet needs has been the identification of blood-based biomarkers closely 30 31correlated with tau PET parameters that reflect brain tau burden, especially in the 32context of selecting suitable patients for anti-amyloid therapies. Recent advances in measurement methodologies have made it possible to quantify 33 minute amounts of proteins in the peripheral blood that are associated with brain 34diseases, thereby enabling the feasibility of blood-based biomarkers¹⁵. Notably, there is 35

36 growing evidence for the clinical significance of plasma phosphorylated tau (p-tau)

assays in detecting AD pathology $^{16-19}$, similar to CSF biomarkers. The C-terminal 1 portion of the tau protein, which predominantly constitutes neurofibrillary tangles²⁰, is $\mathbf{2}$ seldom detectable in biofluids^{21–23}. Most of the current immunoassays for plasma p-tau, 3 4 therefore, employ a pair of antibodies, one of which recognizes the phosphorylated residues, such as Thr181, Thr217, and Thr231, in the mid-portion, while the other 56 identifies the N-terminal region of the tau protein. Accordingly, currently available $\overline{7}$ immunoassays for plasma p-tau detect C-terminally truncated p-tau containing the N-terminus to the mid-domain (N-p-tau)¹². Plasma p-tau levels quantified using these 8 N-p-tau assays can accurately differentiate between AD pathology and other tauopathies 9 with high diagnostic accuracy^{17,18,24,25} and help predict future cognitive decline from 10 prodromal phases^{26,27}. However, one of the significant problems in the clinical use of 11 N-p-tau assays is their inability to be considered as a surrogate marker for tau burden in 12the brain²⁸ given that the measurements obtained had a more pronounced association 13with amyloid PET than with tau PET^{29-32} . Therefore, the need for developing 14blood-based tau biomarkers strongly correlated with PET-detectable tau accumulations 1516in the brain remains unmet. 17The present study aimed to formulate a novel p-tau assay that can be 18interchangeable with the tau PET study. Considering that the truncation of the N-terminal of the tau protein may occur subsequent to the truncation of its C-terminal 19with the formation of neurofibrillary tangle³³, we hypothesized that the levels of both N-20and C-terminally truncated p-tau181 fragments could be correlated with the abundance 2122of tau aggregates in the brain. Thus, we developed a novel mid-region-directed p-tau181 assay by modifying the formerly established N-p-tau181 assay¹⁶. To validate our 2324hypothesis, we collected plasma samples from subjects who underwent PET with both ¹¹C-Pittsburgh Compound B (¹¹C-PiB) and ¹⁸F-florzorotau (aka PM-PBB3/APN-1607) 25for the examination of A β and tau depositions in the brain, respectively.^{34,35} We 26demonstrated a strong correlation of between plasma levels of p-tau181 fragments 2728measured using our mid-region-directed assay (hereinafter called mid-p-tau181) and tau 29PET tracer retention but no linear correlation between plasma N-p-tau181 levels and tau 30 PET data, suggesting the clinical usefulness of the novel assay as a surrogate biomarker 31for PET-visible tau pathologies.

32

33 Results

34 Validation of the newly developed mid-p-tau181 assay

35 The plasma mid-p-tau181 assay exhibited high analytical performance (Supplementary

Methods and Results, Supplementary Tables 1–3, Supplementary Figures 1–5), with high

- 1 precision within and between runs. Spike recovery experiments and parallelism of
- 2 serially diluted plasma samples confirmed the reliability of the measurements.
- 3

4 Demographic data

- 5 Table 1 summarizes the demographic information of the participants. All participants (n
- 6 = 164) underwent neuropsychological assessment, including the Clinical Dementia
- 7 Rating (CDR) scale, Mini-Mental State Examination (MMSE), and frontal assessment
- 8 battery (FAB), simultaneous amyloid and tau PET imaging, and blood sampling on the
- 9 day of the PET examination. Cognitively normal (CN) individuals exhibiting negative
- 10 results on amyloid and tau PET imaging were designated into the CN cohort. Patients
- 11 with mild cognitive impairment (MCI) and AD who had positive amyloid PET findings
- 12 were categorized into the AD continuum group (dubbed AD group). Furthermore,
- 13 subjects with progressive supranuclear palsy (PSP) and other frontotemporal lobar
- 14 degeneration (FTLD) who had negative amyloid PET findings were classified into the
- 15 PSP and FTLD cohorts, respectively. No significant differences in age, years of
- 16 schooling, and gender were observed among the groups. All patient groups showed lower
- 17 MMSE (CN, 29.3 \pm 1.0; AD, 21.9 \pm 4.1; PSP, 24.8 \pm 5.8; FTLD, 23.8 \pm 6.1) and FAB
- 18 scores (CN, 16.7 \pm 1.2; AD, 13.0 \pm 3.0; PSP, 12.0 \pm 3.6; FTLD, 11.0 \pm 4.8) than the CN
- 19 group (p < 0.05, Table 1). Notably, 90% of the AD group comprised subjects with
- 20 early-stage AD who had a CDR score of 0.5 or 1 accounted; however, the mean MMSE
- scores of this group were lower than those of the PSP group (p < 0.05, Table 1) but did not
- significantly differ from those of the FTLD group.
- 23

Significant linear correlation between plasma mid-p-tau181 but not N-p-tau181 with tau PET findings in patients with AD continuum

- 26 We found a significant linear correlation between the plasma mid-p-tau181 levels and tau
- 27 PET tracer retention in patients with AD continuum (Figure 1). Voxel-wise analyses
- revealed a positive correlation between plasma mid-p-tau181 levels and tracer binding in
- the temporal and parietal cortices [Figure 1A; p < 0.05, corrected for family-wise error
- 30 (FWE)]. This finding was corroborated by the following three different quantitative
- ³¹ indices based on a region of interest (ROI): (1) standardized uptake value ratio (SUVR)³⁶
- in the temporal meta-ROI that characterizes tau lesions in AD^{37} ; (2) AD tau score, which
- is a machine learning-based measure indicating AD-related features of tau PET images³⁵;
- and (3) Braak staging SUVRs based on the neuropathological hypothsesis³⁶
- 35 (Supplementary Figure 6). These AD signature ROI analyses revealed significant linear
- 36 correlations between plasma mid-p-tau181 levels and temporal meta-ROI SUVRs (r =

0.506; p = 0.0003), AD tau scores (r = 0.556; p = 0.0003), and SUVRs in the Braak stage 1 $\mathbf{2}$ III/IV limbic (r = 0.403; p = 0.003) and V/VI neocortical (r = 0.508; p = 0.0003) but not 3 Braak stage I/II entorhinal (r = 0.216; p = 0.149) ROIs. These findings clearly 4 demonstrate that plasma mid-p-tau181 levels could accurately reflect AD-related tau accumulation that spreads from the entorhinal cortex first to the inferior temporal lobe 56 and then to the parieto-occipital regions of the neocortex but not tau accumulation in the 7 Braak I/II region. 8 Conversely, the conventional N-p-tau181 assay (Simoa pTau-181 Advantage V2.1 kit, Quanterix, MA, USA) showed no significant linear correlations with tau PET tracer 9 retention (Figure 2). Voxel-based analysis revealed a weak correlation between the 10 aforementioned parameters in the temporal cortex (Figure 2A; p < 0.05, uncorrected); 11 12however, no significant correlation was observed upon correction for multiple 13comparisons (p < 0.05, FWE-corrected). Moreover, none of the three ROI-based analyses revealed significant linear correlations between N-p-tau181 levels and PET parameters (p 14< 0.05, after Bonferroni's correction). Instead, these examinations showed inverse 1516U-shaped nonlinear correlations between plasma N-p-tau181 levels and tau PET SUVRs in the temporal meta-ROI ($R^2 = 0.402$), AD tau score ($R^2 = 0.147$), and Braak stage III/IV 17

- 18 $(R^2 = 0.307)$ and V/VI ROIs $(R^2 = 0.223)$ but not Braak stage I/II ROIs (Figure 2B, C).
- 19

20 Discriminating between tau PET statuses using plasma mid-p-tau181 levels

21Using three different ROI-based methods, we qualitatively assessed the PET-detectable 22tau burden in the CN subjects and AD continuum patients. Thereafter, receiver operating 23characteristic (ROC) curve analyses were conducted to determine plasma mid-p-tau181 cutoff levels for discriminating between individuals with positive and negative AD-type 24tau PET findings. The PET finding classification was based on the cutoff values of 25imaging-based Braak staging, temporal meta-ROI SUVR, and AD tau score. The Braak 26stage in each subject was determined according to the ROI with the highest Z-score (see 27Methods for detailed procedures), with stages 0 and I/II indicating tau-negative and 2829stages III/IV and V/VI being classified as tau-positive (Supplementary Table 4). The cutoff values for the meta-ROI SUVR and AD tau score were determined using ROC 30 curve analyses in the current and previous studies³⁵, respectively. Consequently, our 31findings showed that tau-positive AD cases had significantly higher plasma 32mid-p-tau181 concentrations than did tau-negative AD and CN cases (Figure 3A; p < 133 0.0001). Furthermore, area under the ROC curve (AUC) values during ROC analyses of 3435 mid-p-tau181 levels to different between tau PET positivity and negativity defined by all three methods exceeded 0.85 (Table 2, Figure 3B), indicating that this plasma 36

1 biomarker with reference to PET-based classifications had robust discriminative power.

 $\mathbf{2}$

3 Head-to-head comparisons between two p-tau181 assays according to their correlation

4 with non-tau imaging biomarkers

5 Next, we examined whether plasma p-tau181 levels determined by either the

6 pre-established or newly developed assay were correlated with the abundance of

7 cerebral amyloid accumulations evaluated using PiB-PET (Supplementary Figure 7).

- 8 Notably, none of the measures obtained using these p-tau181 assays were correlated
- 9 with voxel-based and ROI-based quantitative values of amyloid burden. Meanwhile,
- 10 voxel-based morphometry revealed significant negative correlations between the plasma
- 11 mid-p-tau181 concentration and gray matter volume in the neocortex, primarily in the
- 12 temporal and parietal areas (Figure 4). The ROI-based analysis also confirmed a
- 13 correlation between mid-p-tau181 and cortical thinning in AD-signature regions defined

14 as described elsewhere³⁸ (r = -0.406; p = 0.005). In contrast, N-p-tau181 did not exhibit

15 any correlation with structural imaging measures.

16

17 Comparison among blood-based biomarkers according to diagnostic performance for 18 AD

19 Figure 5A illustrates group comparisons of four AD-related plasma biomarkers,

20 including the mid-p-tau181 measured using our in-house assay, with and the

21 corresponding values for each diagnostic group being presented in Table 1. Our results

indicated significant differences in A β 42/40 and N-p-tau181 concentrations between the

AD and other groups. Additionally, the AD group exhibited significantly higher

24 mid-p-tau181 concentrations than did all other groups except the PSP group. Moreover,

- all disease groups had increased neurofilament light chain (NfL) concentrations
- compared to the CN group. ROC curve analyses (Figure 5B) revealed the following
- 27 order of biomarkers according to their ability to discriminate between individuals with
- and without ¹¹C-PiB-PET-positive amyloid pathology when all participants were

```
29 incorporated: N-p-tau181 (AUC = 0.867), A\beta 42/40 (AUC = 0.850), mid-p-tau181
```

30 (AUC = 0.771), and NfL (AUC = 0.555).

31

32 Trajectory analyses of imaging- and blood-based A/T/N biomarkers along with

- 33 cognitive decline in the CN and AD continuum subjects
- 34 The imaging biomarkers examined in this cohort revealed that the A marker (i.e.,
- amyloid PET index) displayed a sigmoidal trajectory when plotted against cognitive
- deficits and reached a plateau when the MMSE score was around 20 points, the point at

which cognitive decline became apparent (Figure 6A). Conversely, the T marker (i.e.,
tau PET index) displayed a linearly progressive increase with a decrease in the MMSE
scores. The N marker (i.e., the volumetric MRI index) also tended to show a linear
increment similar to that for the T marker, albeit with a lesser z-score range.

The blood-based biomarkers displayed trajectories closely resembling those of the 56 imaging biomarkers, although their dynamic ranges were inferior to those of the imaging biomarkers (Figure 6B). Notably, the two different blood-based T markers 7 8 showed clearly distinct trajectories such that plasma mid-p-tau181 levels exhibited a 9 linearly progressive increase similar to the tau PET index with the decline in MMSE scores, whereas plasma N-p-tau181 levels measured using a currently widely used 10 11 conventional p-tau assay (Quanterix) displayed a sigmoidal trajectory similar to that for 12amyloid PET with the decrease in MMSE scores. The A (A β 42/40) and N (NfL) 13markers showed a sigmoidal curve and a linear progression, respectively, similar to those for the corresponding imaging biomarkers. 14

15

16 Discussion

The current study aimed to develop a novel plasma p-tau biomarker (mid-p-tau181) that 17could be potentially interchangeable with tau PET imaging and validate its ability to 18accurately reflect the extent of AD-type tau burden in the brain confirmed using tau PET. 19Notably, our results showed that the plasma mid-p-tau181 exhibited a strong correlation 2021with the accumulation of tau PET ligands in AD brains and was accordingly able to 22discriminate positive and negative AD pathologies on tau PET. These findings indicate 23that plasma mid-p-tau levels could have sufficient accuracy in determining the existence of AD-type tau pathology in the brain without being affected by brain amyloid 24deposition, which has been known to affect the plasma levels of N-terminal to 25mid-domain forms of p-tau181 (N-p-tau) detected as plasma p-tau181 by most 26conventional p-tau assays.^{17,26} Moreover, the trajectory of the change in the plasma 2728levels of the mid-p-tau181 along with MMSE scores was similar to that observed with 29tau PET. These results strongly suggest the potential utility of plasma mid-p-tau181 as a 30 blood-based biomarker for the detection and stratification of AD-type tau burden in the 31brain, mainly in the tau accumulation phase of the AD continuum. 32Various experimental and clinical studies have suggested that an increase in soluble p-tau in biofluids could be strongly associated with A β aggregation.^{17,29,30,39–42} This 33

34 evidence indicates that tau hyperphosphorylation occurs in neurons exposed to A β , with

35 p-tau levels increasing in response to A β deposition. Consistent with this notion, plasma

36 p-tau is highly valuable for distinguishing AD from other neurodegenerative

diseases.^{18,43–45} In addition, p-tau concentrations measured using conventional N-p-tau 1 assays have been recognized as an early marker for AD given the increase in their $\mathbf{2}$ values alongside A β deposition^{17,44,46–49} rather than before tau aggregation.^{19,28,30} 3 4 Meanwhile, the process of tangle maturation also needs to be considered when interpreting the levels of soluble p-tau in biofluids measured using immunoassay 56 methodologies. Most current approaches for quantifying soluble p-tau via immunoassay predominantly target tau fragments phosphorylated at positions 181, 217, or 231 and 7 bearing N-terminal epitopes.¹² The C-terminal portion of the tau protein, which is 8 involved its aggregation,⁵⁰ is rarely present in soluble species of the tau protein. Thus, 9 soluble tau fragments present in the body fluids usually include only the 10 N-terminal-to-mid-region epitopes, ensuring consistent quantification using N-p-tau 11 assays currently accessible.¹² Conversely, N-terminal cleavage also occurs in addition to 12its C-terminal cleavage in tau proteins insolubilized and deposited in the brain, which 13has been postulated to play a role in tangle evolution.^{33,51–53} Therefore, this tau 14truncation implies that the accumulation of tau aggregates in the brain might not directly 1516correspond with soluble p-tau quantified using conventional N-p-tau assays. Concurrent with this perspective, a study investigating the associations between various plasma 1718 p-tau species and amyloid/tau PET demonstrated that all plasma p-tau species measured by N-p-tau assays showed a considerably stronger correlation with amyloid PET 19binding than with tau PET binding.³⁰ These findings support the notion that currently 20available p-tau assays cannot be interchangeable with tau PET given that they do not 2122accurately coincide with tau PET results and are also affected by amyloid deposition. 23Conversely, our mid-p-tau181 assay demonstrated a strong correlation with tau PET accumulation, but not with the amyloid PET ligand, in AD brains. The tau PET 24ligand employed in the current study, namely Florzorotau, exhibits high sensitivity to 25AD-specific tau lesions, including neurofibrillary tangles, neuropil threads, and neuritic 26plaques.³⁴ This suggests that our plasma mid-p-tau181, which is a previously 2728nonexistent blood-based "T" biomarker in the ATN framework, corresponded to the 29AD-type tau accumulation in tau PET scans. Moreover, the characteristics of mid-p-tau181 suggest its usefulness as a biomarker 30 31for predicting the therapeutic response to current DMTs targeting $A\beta$. These therapies are more likely to be effective when introduced before substantial tau aggregation. 32^{2,11,54,55} Therefore, identifying patients with high plasma mid-p-tau levels, in whom 33 brain tau aggregation has been suggested to have progressed beyond the critical point, 34could help select patients more likely to benefit from DMTs targeting A β , like so in the 35 phase 3 study of donanemab.¹¹ Our results showed that our plasma mid-p-tau181 could 36

discriminate between tau-positive and -negative subjects with a specificity greater than
 85%, effectively excluding patients with advanced tau pathology.

3 Plasma mid-p-tau181 levels were also correlated with brain atrophy and increased 4 with the progression of cognitive impairment evaluated using MMSE scores during trajectory analysis. Meanwhile, plasma N-p-tau181 levels increased in the early stage 5even when MMSE scores were within the normal range, and its increase slowed down 6 7 in the later phase when cognitive impairment advanced. In support of these findings, 8 CSF p-tau181 measured with an immunoassay targeting the mid-portion of tau protein also increased later than N-p-tau181,⁴⁹ as observed in our study. However, the increase 9 in CSF N-p-tau181 species ceased and instead decreased after neuronal dysfunction 10 started in the familial AD cohort.⁵⁶ Consequently, plasma mid-p-tau181 has been 11 associated with the later stages of AD in contrast to N-p-tau181, which has been 1213associated with the early stage just after amyloid deposition starts. Mid-p-tau181 could thus be utilized as a biomarker to monitor disease progression when cognitive 1415impairment starts worsening due to tau accumulation in the brain.

16The PSP group also showed a significant elevation in plasma mid-p-tau181, deviating from the results of the N-p-tau assay and leading to a slight decrease in 17specificity to AD. Phosphorylation in the mid-region has also been observed in non-AD 18tauopathies, such as PSP,⁵⁷ with some previous studies reporting that soluble p-tau 19levels in CSF might be elevated in non-AD tauopathies.^{58,59} However, plasma 20mid-p-tau181 levels were not correlated with tau PET accumulation in the PSP patients 2122(Supplementary Figure 8). Accordingly, the underlying pathophysiological basis for the 23observed increase in plasma mid-p-tau181 levels in our PSP group remains elusive. 24Although further investigations are still needed, plasma mid-p-tau181 might be a 25valuable biomarker for non-AD tauopathies.

26This study has several limitations worth noting. Firstly, our sample size was 27modest, and longitudinal data was absent. As such, we are planning to conduct more 28studies in the near future to address these limitations. Secondly, we found that no 29correlation between the extent of amyloid burden in the brain evaluated through 30 amyloid PET and not only plasma mid-p-tau181 levels but also N-p-tau181 levels in contrast to previous reports, which have shown a positive correlation between brain 31amyloid burden and plasma N-p-tau.^{26,30,32} This discrepancy may be attributed to the 32demographics of the patients with AD continuum included in the current study, who 33 predominantly comprise symptomatic AD cases and whose amyloid deposition in the 3435 brain has already plateaued. To confirm this phenomenon, we conducted correlation analyses between plasma p-tau181 levels and PET findings in the study participants, 36

1 including both the CN and AD continuum subjects (Supplementary Figure 9).

2 Consistent with previous reports,^{30,32} plasma N-p-tau181 levels were primarily

- 3 correlated with amyloid PET results, whereas plasma mid-p-tau181 levels were
- 4 correlated chiefly with tau PET results. Further validation of interactions between
- 5 plasma p-tau species and amyloid/tau PET results are still required in independent
- 6 cohorts, including very early AD cases, such as those with asymptomatic AD [A(+)T(-)].
- 7 Additional validation studies using alternative tau PET tracers, such as ¹⁸F-MK6240,
- 8 would certainly be informative. Moreover, although this study developed the
- 9 mid-p-tau181 assay, the characteristics of plasma p-tau biomarkers, including which AD
- 10 continuum stages a specific plasma p-tau molecule could reflect most, could vary
- depending on the phosphorylation site on the p-tau molecules.^{56,60} Given some previous
- 12 reports indicating a moderate correlation between p-tau217 and tau pathologies in the
- AD brain,^{18,19,32} it is also intriguing to develop other assays targeting mid-p-tau species
 with phosphorylation sites other than 181.
- 15Despite these limitations, the strength of the present study lies our development of 16an innovative mid-p-tau assay that corresponds with the AD-type brain tau burden determined using tau PET and its validation in a cohort of controls and AD continuum 17subjects who underwent both amyloid- and tau PET. Although specific assays have been 18reported to measure tau fragments in the CSF and exhibit correlations with brain tau 19pathologies,^{61,62} there are still unmet needs for implementing comprehensively validated 20blood-based biomarkers that accurately reflect brain tau burden without being 2122influenced by amyloid deposition. Our novel mid-p-tau assay is anticipated to function 23as a blood-based biomarker for the screening and monitoring of brain tau pathologies, especially in the selection of patients most suitable for anti-A^β DMTs and the 2425development of tau-targeted therapies, although further longitudinal studies and 26validation in larger cohorts are necessary.
- 27

28 Methods

29 Participants

- 30 We recruited a cohort of 186 individuals comprising 43 CN individuals, 30 patients with
- MCI due to AD, 31 patients with dementia due to AD, 52 patients with PSP, and 30
- 32 patients with other FTLD syndromes between January 2018 and September 2022. The
- 33 other FTLDs comprised 12 cases with corticobasal syndrome (CBS), 10 cases with
- 34 behavioral-variant frontotemporal dementia (BvFTD), 7 cases with frontotemporal
- dementia and parkinsonism linked to chromosome 17 MAPT (FTDP-17/MAPT), and 1
- 36 case of primary progressive aphasia. CN individuals were those aged older than 40 years

who had no history of neurological and psychiatric disorders, had a MMSE score of ≥ 28 , 1 or had a Montreal Cognitive Assessment score of ≥26 and Geriatric Depression Scale $\mathbf{2}$ score of ≤ 5 .³⁵ Patients with MCI and dementia due to AD underwent clinical evaluations. 3 Cognitive impairment severity was defined as MMSE < 24 and CDR \geq 1 for dementia 4 and MMSE ≥ 26 and CDR = 0.5 for MCL³⁵ Patients with PSP and other FTLD 5syndromes were diagnosed according to established criteria previously reported.^{34,35} 6 $\overline{7}$ In the present study, the diagnosis of patients with MCI and dementia due to AD 8 required brain amyloid positivity in PET scans, and they were combined and categorized 9 into the AD group based on the concept of the AD continuum. We excluded patients with PSP and other FTLD who had positive amyloid PET results to eliminate the influence of 10 mixed pathology. Those with other FTLDs were heterogeneous and categorized into the 11 12FTLD group. Furthermore, CN individuals with a positive result on either or both amyloid and tau PET scans were also excluded as they were considered to have been in 13the preclinical AD stage. Amyloid positivity was defined based on ¹¹C-PiB-PET visual 14inspection performed by a minimum of three specialists with expertise in the field.³⁴ Tau 15PET negativity in CN individuals was defined according to the AD tau score (< 0.1986) 16and PSP tau score (< 0.3431) as reported previously.³⁵ These scores, which were 17calculated from ¹⁸F-florzorotau PET images via our established machine learning 18 algorithm, possess a high degree of sensitivity and specificity in discriminating CN 19individuals from patients with AD and PSP.35 Consequently, after excluding 3 CN 20individuals and 11 MCI, 2 AD, 2 PSP, and 4 FTLD patients according to the 2122aforementioned criteria, our final cohort consisted of 164 participants comprising 40 CN 23individuals and 48 AD, 50 PSP, and 26 FTLD patients. This study was approved by the National Institutes for Quantum Science and 24Technology Certified Review Board. Written informed consent was obtained from all 25participants and spouses or close family members when participants were cognitively 26impaired. This study was registered with the UMIN Clinical Trial Registry 2728(UMIN-CRT; number 000041383).

29

30 Blood sampling

31 We obtained blood samples through venous puncture on the same day as the PET scan. A

- 32 total of 8 mL of blood was collected in ethylenediaminetetraacetic acid
- 33 (EDTA)-containing tubes. After collection, plasma was separated by centrifugation for 10
- ³⁴ min at 2000g, aliquoted into polypropylene tubes, and then stored at –80°C until analysis.
- 35

36 Measurements of blood biomarkers

1 We developed a novel immunoassay able to quantify plasma levels of both N- and

- 2 C-terminally truncated p-tau181 fragments run on a highly sensitive automated digital
- 3 ELISA platform (Simoa HD-X Analyzer, Quanterix, Lexington, KY, USA) and measured
- 4 the levels of p-tau181 including such fragments in human plasma. The details of the
- 5 procedures for method validation of this original immunoassay are described in the
- 6 Supplementary Methods and Results. We also quantified plasma levels of the A/T/N
- biomarkers⁷ (A β 42, A β 40, p-tau181, and NfL instead of total tau in the original paper)
- 8 utilizing the Simoa platform (Quanterix) equipped with validated assay kits. Procedures
- 9 were performed following the manufacturer's instructions. This study employed the
- 10 Aβ42/Aβ40 ratio as a proxy for cerebral amyloid burden. Plasma p-tau181 measured
- 11 using the commercial kit (Simoa pTau-181 V2.1 Assay, Quanterix) was defined as
- 12 N-p-tau181, whereas plasma p-tau181 measured using the originally developed

13 immunoassay run on the Simoa system was defined as mid-p-tau181.

All plasma samples were diluted four times with the respective sample diluent
before the assays to minimize matrix effects. All plasma samples were run in duplicate
with the same lot of standards. The relative concentration estimates of plasma biomarkers
were calculated according to their respective standard curves.

18

19 **PET and MRI data acquisition**

Amyloid and tau deposits in the brains of all participants were assessed using PET with 20¹¹C-PiB and ¹⁸F-florzorotau as described in other clinical trials (UMIN-CRT; number 2122000026385, 000026490, 000029608, 000030248, and 000043458). One PSP patient who had already been confirmed to be A β -negative at another facility no longer underwent 23¹¹C-PiB-PET at our center. The scan protocol was described as follows: parametric 24¹¹C-PiB-PET images were acquired 50–70 min after injection (injected dose: 528.5 ± 65.5 25MBq, molar activity 90.2 \pm 26.2 GBq/µmol); ¹¹⁸F-florzorotau PET images were obtained 2690–110 min after injection (injected dose: 186.6 ± 7.4 MBq, molar activity 244.2 ± 86.7 27GBq/µmol). PET was primarily conducted using a Biograph mCT flow system (Siemens 28Healthcare), with some cases using the Discovery MI (GE Healthcare) (9¹¹C-PiB scans 29in CN individuals; 22 ¹¹C-PiB scans and 3 ¹⁸F-florzorotau scans in AD patients; 7 ¹¹C-PiB 30 scans in PSP patients; and 4¹¹C-PiB scans in FTLD patients) and an ECAT EXACT HR+ 31scanner (CTI PET Systems, Inc.) (three ¹¹C-PiB scans in CN individuals, four ¹¹C-PiB 32scans in AD patients, nine ¹¹C-PiB scans in PSP patients, and three ¹¹C-PiB scans in 33 FTLD patients). Acquired PET images were reconstructed using the filtered back 34projection method with a Hanning filter. MRI examination was conducted simultaneously 35 36 with PET using a 3-T scanner (MAGNETOM Verio; Siemens Healthcare). The

1 anatomical images were acquired using a three-dimensional T1-weighted gradient echo

sequence that produced a gapless series of thin sagittal sections (TE = 1.95 ms, TR = 2300

- 3 ms, TI = 900 ms, flip angle = 9°, acquisition matrix = $512 \times 512 \times 176$, voxel size = $1 \times$
- 4 $0.488 \times 0.488 \text{ mm}^3$).
- 5

6 Imaging analyses

- 7 All images were preprocessed using PMOD software (version 4.3, PMOD Technologies
- 8 Ltd), FreeSurfer 6.0 (http://surfer.nmr.mgh.harvard.edu/), MATLAB (The Mathworks,
- 9 Natick, MA, USA), and Statistical Parametric Mapping software (SPM12, Wellcome

10 Department of Cognitive Neurology). PET images were co-registered with individual

anatomical T1-weighted MR images, and SUVR images were generated using each

12 reference region. The cerebellar cortex was the reference region for the ¹¹C-PiB-PET

13 images. For ¹⁸F-florzorotau PET images, an optimized reference region was set through

14 an in-house MATLAB script that considered the distribution of diverse tau lesions

15 throughout the entire gray matter and extracted optimized reference regions on an

16 individual basis.⁶³ Each PET and MR image was also normalized to the Montreal

17 Neurologic Institute space using the Diffeomorphic Anatomical Registration Through

18 Exponentiated Lie Algebra (DARTEL) algorithm and was smoothed with a Gaussian

19 kernel at 8-mm full-width at half maximum in voxel-wise analyses.

20We performed an ROI analysis targeting AD pathologies on each imaging modality 21to quantify the regional amyloid/tau burden and cortical thinning. The amyloid burden 22was assessed using a Centiloid atlas (frontal, temporal, parietal, precuneus, anterior 23striatum, and insula) implemented in the PMOD Neuro Tool (PMOD Technologies Ltd). 24Each Centiloid SUVR was calculated and converted to a Centiloid score (CL score)⁶⁴ using PET data from 12 young CN individuals aged 23-43 years and 25 cases of AD 25patients scanned at our institution. Tau burden was assessed using ROIs targeting tau 26pathology associated with AD labeling through FreeSurfer, Braak staging ROIs (I/II, 27III/IV. V/VI),³⁶ and temporal meta-ROI (entorhinal, amygdala, parahippocampal, 28

²⁹ fusiform, inferior temporal, and middle temporal).³⁷ We excluded the hippocampus from

30 the Braak stage I/II ROI because of potential spill-in from the choroid plexus.³⁴

Additionally, we also estimated the AD tau score to assess AD-type tau burden in the

32 brain, which was calculated using an Elastic Net model trained on tau PET data as

³³ previously reported.³⁵ A qualitative analysis based on the values obtained from these

ROI analyses was also conducted to evaluate the presence of tau lesions. For Braak

35 staging, the SUVR values were converted to z-values based on another young CN

36 cohort, and the highest stage was assigned based on the average regional Z-score (>2.5).

- 1 Those with stages 0–I/II were classified as tau-negative, whereas those with stages
- 2 III/IV–V/VI were classified as tau-positive. The cutoff value of temporal meta-ROI
- 3 SUVR was set at 1.105 to maximize the differentiation between CN individuals and AD
- 4 patients during ROC analysis (see Supplementary material for detailed information).
- 5 and the cutoff value of AD tau score was set at 0.1986 as described elsewhere.³⁵
- 6 Cortical thickness was measured using the cortical signature of AD through FreeSurfer
- 7 (medial temporal, inferior temporal, temporal pole, angular, superior frontal, superior
- 8 parietal, supramarginal, precuneus, and middle frontal).³⁸
- 9

10 Statistical analyses

11 Statistical analyses were conducted using GraphPad Prism version 9 (GraphPad

- 12 Software). Initially, group comparisons were performed using the Kruskal–Wallis test or
- 13 Mann–Whitney U test for demographic data and measured blood biomarker values and
- 14 Fisher's exact test for gender (p < 0.05, corrected by Dunn's multiple comparisons).
- 15 Subsequently, correlation analyses were conducted to verify the association between each
- 16 p-tau181 assay and each imaging biomarker. During voxel-based analyses, a linear
- 17 regression model was applied using SPM12. The extent threshold was established based
- 18 on the expected voxels per cluster. For multiple voxel comparisons, family-wise error
- 19 corrections at the cluster level were applied (p < 0.05, FWE-corrected). During
- 20 ROI-based analyses, Pearson's correlation analyses were performed (p < 0.05, corrected
- 21 by Bonferroni multiple comparisons), and nonlinear regression analysis (quadratic) was
- 22 conducted when no significant correlation was observed. Results were adopted when the
- 23 nonlinear analysis based on Akaike's Information Criterion (AIC) showed a better fit than
- the linear one. In addition, ability of each blood biomarker to discriminate between the
- 25 presence or absence of AD pathology, as defined by amyloid or tau PET positivity, was
- also evaluated by calculating AUC values from ROC curve analyses. The Youden index
- 27 maximizing sensitivity plus specificity minus one determined the optimized cutoff value.
- 28 Finally, to explore the trajectories from CN to AD for each blood/imaging biomarker, we
- 29 converted each biomarker value to a z-value based on CN data. Thereafter, we examined
- 30 their relationship with cognitive dysfunction (MMSE score). A linear or sigmoidal 4PL
- regression analysis was adapted, and the better-fitting model was selected based on AIC.
- 32

33 Data availability

34 The data supporting this study's findings are available from the corresponding author on

- 35 reasonable request. Sharing and reuse of data require the expressed written permission
- ³⁶ of the authors, as well as clearance from the Institutional Review Boards.

1

2 References

3	1.	Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and
4		forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study
5		2019. The Lancet Public Health 7, e105-e125 (2022).
6	2.	Cummings, J. et al. Alzheimer's disease drug development pipeline: 2022.
7		Alzheimers Dement. (N. Y.) 8, e12295 (2022).
8	3.	EMERGE and EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to
9		Evaluate Aducanumab in Patients With Early Alzheimer's Disease
10		(https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f).
11		2019.
12	4.	Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The
13		TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023).
14	5.	van Dyck, C. H. et al. Lecanemab in early Alzheimer's disease. N. Engl. J. Med.
15		388 , 9–21 (2023).
16	6.	Imbimbo, B. P., Ippati, S., Watling, M. & Balducci, C. A critical appraisal of
17		tau-targeting therapies for primary and secondary tauopathies. Alzheimers. Dement.
18		18 , 1008–1037 (2022).
19	7.	Jack, C. R., Jr et al. NIA-AA Research Framework: Toward a biological definition
20		of Alzheimer's disease. Alzheimers. Dement. 14, 535-562 (2018).
21	8.	Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L. & Rowe, C. C. Imaging
22		tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. <i>Nat</i> .
23		<i>Rev. Neurol.</i> 14 , 225–236 (2018).
24	9.	Teng, E. et al. Safety and efficacy of semorinemab in individuals with prodromal to
25		mild Alzheimer disease: A randomized clinical trial. JAMA Neurol. 79, 758–767
26		(2022).
27	10.	Sevigny, J. et al. The antibody aducanumab reduces Aß plaques in Alzheimer's
28		disease. Nature 537, 50–56 (2016).
29	11.	Mintun, M. A., Wessels, A. M. & Sims, J. R. Donanemab in early Alzheimer's
30		disease. Reply. The New England journal of medicine vol. 385 667 (2021).
31	12.	Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis,
32		interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400-418 (2022).
33	13.	Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the
34		IWG-2 criteria. Lancet Neurol. 13, 614–629 (2014).
35	14.	McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease:
36		recommendations from the National Institute on Aging-Alzheimer's Association

1		workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers. Dement.
2		7, 263–269 (2011).
3	15.	Hansson, O. et al. The Alzheimer's association appropriate use recommendations
4		for blood biomarkers in Alzheimer's disease. Alzheimers. Dement. 18, (2022).
5	16.	Tatebe, H. et al. Quantification of plasma phosphorylated tau to use as a biomarker
6		for brain Alzheimer pathology: pilot case-control studies including patients with
7		Alzheimer's disease and down syndrome. Mol. Neurodegener. 12, 63 (2017).
8	17.	Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's
9		disease: a diagnostic performance and prediction modelling study using data from
10		four prospective cohorts. Lancet Neurol. 19, 422-433 (2020).
11	18.	Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for
12		Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772-781
13		(2020).
14	19.	Janelidze, S. et al. Associations of Plasma Phospho-Tau217 Levels With Tau
15		Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 78,
16		149–156 (2021).
17	20.	Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer's
18		disease. Nature 547, 185–190 (2017).
19	21.	Koss, D. J. <i>et al.</i> Soluble pre-fibrillar tau and β -amyloid species emerge in early
20		human Alzheimer's disease and track disease progression and cognitive decline.
21		Acta Neuropathol. 132, 875–895 (2016).
22	22.	Han, P. et al. A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion
23		Factor. J. Neuropathol. Exp. Neurol. 76, 44-51 (2017).
24	23.	Sato, C. et al. Tau Kinetics in Neurons and the Human Central Nervous System.
25		Neuron 98, 861–864 (2018).
26	24.	Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in
27		Alzheimer's disease and frontotemporal lobar degeneration. Nat. Med. 26, 387–397
28		(2020).
29	25.	Lantero Rodriguez, J. et al. Plasma p-tau181 accurately predicts Alzheimer's
30		disease pathology at least 8 years prior to post-mortem and improves the clinical
31		characterisation of cognitive decline. Acta Neuropathol. 140, 267–278 (2020).
32	26.	Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression
33		of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol.
34		Psychiatry 26, 429–442 (2021).
35	27.	Palmqvist, S. et al. Prediction of future Alzheimer's disease dementia using plasma
36		phospho-tau combined with other accessible measures. Nat. Med. 27, 1034–1042

1 (2021).

-		
2	28.	Groot, C. et al. Phospho-tau with subthreshold tau-PET predicts increased tau
3		accumulation rates in amyloid-positive individuals. Brain (2022)
4		doi:10.1093/brain/awac329.
5	29.	Mattsson-Carlgren, N. et al. Soluble P-tau217 reflects amyloid and tau pathology
6		and mediates the association of amyloid with tau. EMBO Mol. Med. 13, e14022
7		(2021).
8	30.	Therriault, J. et al. Association of Phosphorylated Tau Biomarkers With Amyloid
9		Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA
10		Neurol. (2022) doi:10.1001/jamaneurol.2022.4485.
11	31.	Smirnov, D. S. et al. Plasma biomarkers for Alzheimer's Disease in relation to
12		neuropathology and cognitive change. Acta Neuropathol. 143, 487–503 (2022).
13	32.	Salvadó, G. et al. Specific associations between plasma biomarkers and
14		postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. e2463 (2023).
15	33.	Guillozet-Bongaarts, A. L. et al. Tau truncation during neurofibrillary tangle
16		evolution in Alzheimer's disease. Neurobiol. Aging 26, 1015–1022 (2005).
17	34.	Tagai, K. et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's
18		and Non-Alzheimer's Disease Tauopathies. Neuron 109, 42-58.e8 (2021).
19	35.	Endo, H. et al. A Machine Learning-Based Approach to Discrimination of
20		Tauopathies Using [18 F]PM-PBB3 PET Images. Mov. Disord. 37, 2236–2246
21		(2022).
22	36.	Schöll, M. et al. PET Imaging of Tau Deposition in the Aging Human Brain.
23		Neuron 89 , 971–982 (2016).
24	37.	Ossenkoppele, R. et al. Discriminative Accuracy of [18F]flortaucipir Positron
25		Emission Tomography for Alzheimer Disease vs Other Neurodegenerative
26		Disorders. JAMA 320, 1151–1162 (2018).
27	38.	Dickerson, B. C. et al. The Cortical Signature of Alzheimer's Disease: Regionally
28		Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD
29		Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals. Cereb.
30		<i>Cortex</i> 19 , 497–510 (2008).
31	39.	Venkatramani, A. & Panda, D. Regulation of neuronal microtubule dynamics by
32		tau: Implications for tauopathies. Int. J. Biol. Macromol. 133, 473–483 (2019).
33	40.	Zhang, F. <i>et al.</i> β -amyloid redirects norepinephrine signaling to activate the
34		pathogenic GSK3β/tau cascade. Sci. Transl. Med. 12, (2020).
35	41.	He, Z. <i>et al.</i> Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies
36		by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29-38 (2018).

1	42.	Maia, L. F. <i>et al.</i> Changes in amyloid- β and Tau in the cerebrospinal fluid of
2		transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5,
3		194re2 (2013).
4	43.	Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression
5		of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
6		<i>bioRxiv</i> (2020) doi:10.1101/2020.07.15.20154237.
7	44.	Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as
8		biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a
9		retrospective diagnostic performance study. Lancet Neurol. 20, 739–752 (2021).
10	45.	Benussi, A. et al. Classification accuracy of blood-based and neurophysiological
11		markers in the differential diagnosis of Alzheimer's disease and frontotemporal
12		lobar degeneration. Alzheimers. Res. Ther. 14, 155 (2022).
13	46.	Mielke, M. M. et al. Comparison of Plasma Phosphorylated Tau Species With
14		Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular
15		Pathology, and Cognitive Outcomes. JAMA Neurol. 78, 1108-1117 (2021).
16	47.	Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in
17		prodromal Alzheimer's disease. Brain (2022) doi:10.1093/brain/awac333.
18	48.	Milà-Alomà, M. <i>et al.</i> Plasma p-tau231 and p-tau217 as state markers of amyloid-β
19		pathology in preclinical Alzheimer's disease. Nat. Med. 28, 1797–1801 (2022).
20	49.	Suárez-Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or
21		T231 rise in the initial stages of the preclinical Alzheimer's continuum when only
22		subtle changes in A β pathology are detected. <i>EMBO Mol. Med.</i> 12 , e12921 (2020).
23	50.	Dujardin, S. et al. Tau molecular diversity contributes to clinical heterogeneity in
24		Alzheimer's disease. Nat. Med. 26, 1256-1263 (2020).
25	51.	García-Sierra, F., Ghoshal, N., Quinn, B., Berry, R. W. & Binder, L. I.
26		Conformational changes and truncation of tau protein during tangle evolution in
27		Alzheimer's disease. J. Alzheimers. Dis. 5, 65-77 (2003).
28	52.	Bondareff, W. et al. Molecular analysis of neurofibrillary degeneration in
29		Alzheimer's disease. An immunohistochemical study. Am. J. Pathol. 137, 711-723
30		(1990).
31	53.	Horowitz, P. M. et al. Early N-terminal changes and caspase-6 cleavage of tau in
32		Alzheimer's disease. J. Neurosci. 24, 7895–7902 (2004).
33	54.	Bloom, G. S. Amyloid- β and tau: the trigger and bullet in Alzheimer disease
34		pathogenesis. JAMA Neurol. 71, 505-508 (2014).
35	55.	Cai, Y. <i>et al.</i> Initial levels of β -amyloid and tau deposition have distinct effects on
36		longitudinal tau accumulation in Alzheimer's disease. Alzheimers. Res. Ther. 15, 30

1	(2023).
---	---------

2	56.	Barthélemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid
3		and the evolution of stages of dominantly inherited Alzheimer's disease. Nat. Med.
4		26 , 398–407 (2020).
5	57.	Kametani, F. et al. Comparison of Common and Disease-Specific Post-translational
6		Modifications of Pathological Tau Associated With a Wide Range of Tauopathies.
7		Front. Neurosci. 14, 581936 (2020).
8	58.	Sato, C. et al. MAPT R406W increases tau T217 phosphorylation in absence of
9		amyloid pathology. Ann Clin Transl Neurol 8, 1817–1830 (2021).
10	59.	Kurihara, M. et al. CSF P-Tau181 and Other Biomarkers in Patients With Neuronal
11		Intranuclear Inclusion Disease. Neurology 100, e1009–e1019 (2023).
12	60.	Barthélemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as
13		a biomarker for the differential diagnosis of Alzheimer's disease and PET
14		amyloid-positive patient identification. Alzheimers. Res. Ther. 12, 26 (2020).
15	61.	Blennow, K. et al. Cerebrospinal fluid tau fragment correlates with tau PET: a
16		candidate biomarker for tangle pathology. Brain 143, 650-660 (2020).
17	62.	Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology
18		in Alzheimer's disease. Nat. Med. 29, 1954–1963 (2023).
19	63.	Tagai, K. et al. An optimized reference tissue method for quantification of tau
20		protein depositions in diverse neurodegenerative disorders by PET with
21		18F-PM-PBB3 (18F-APN-1607). Neuroimage 264, 119763 (2022).
22	64.	Klunk, W. E. et al. The Centiloid Project: Standardizing quantitative amyloid
23		plaque estimation by PET. Alzheimers. Dement. 11, 1 (2015).
24		
25	Fur	nding
26		This study was supported in part by AMED under Grant Numbers JP18dm0207018,
27	JP1	9dm0207072, JP18dk0207026, JP19dk0207049, 21wm0425015h0001, and
28	203	56533; MEXT KAKENHI under Grant Numbers JP16H05324 and JP18K07543;
29	JST	under Grant Numbers JPMJCR1652 and JPMJMS2024; and the Kao Research
30	Cou	ncil for the Study of Healthcare Science, Biogen Idec Inc. and APRINOIA
31	The	rapeutics.
32		
33	Acl	snowledgements
34		The authors thank all patients and their caregivers for participation in this study, as
35	wel	l as clinical research coordinators, PET and MRI operators, radiochemists, and
36	rese	earch ethics advisers at QST for their assistance with the current projects. We thank

1 APRINOIA Therapeutics for kindly sharing a precursor of ¹⁸F-florzorotau. The authors

2 acknowledge support with the recruitment of patients by Shunichiro Shinagawa at the

3 Department of Psychiatry, Jikei University School of Medicine; Shigeki Hirano at the

4 Department of Neurology, Chiba University; Taku Hatano, Yumiko Motoi, and Shinji

5 Saiki at the Department of Neurology, Juntendo University School of Medicine; Ikuko

6 Aiba at the Department of Neurology, National Hospital Organization Higashinagoya

7 National Hospital; Yasushi Shiio and Tomonari Seki at the Department of Neurology,

8 Tokyo Teishin Hospital; Hisaomi Suzuki at the National Hospital Organization

9 Shimofusa Psychiatric Medical Center.

10

11 Author contributions

12 Kenji Tagai, Harutsugu Tatebe: Conceptualization, Methodology, Formal

13 analysis, Writing - original draft. Sayo Matsuura, Zhang Hong: Measurement of

14 samples. Naomi Kokubo, Kiwamu Matsuoka, Hironobu Endo, Asaka Oyama,

15 Kosei Hirata, Hitoshi Shinotoh, Yuko Kataoka, Hideki Matsumoto, Masaki Oya,

16 Shin Kurose, Keisuke Takahata, Masanori Ichihashi, Manabu Kubota, Chie Seki,

17 Hitoshi Shimada, Yuhei Takado: Collection of clinical data. Kazunori Kawamura,

18 Ming-Rong Zhang: Radioligand synthesis. Yoshiyuki Soeda, Akihiko Takashima:

19 Assay validation. Makoto Higuchi, Takahiko Tokuda: Conceptualization, Writing -

20 review & editing, Funding acquisition, Supervision

21

22 Competing interests

23 Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on

compounds related to the present report (JP 5422782/EP 12 884

25 742.3/CA2894994/HK1208672).

1	Table 1	. Demographic	and blood	biomarker	data of t	he participants.
---	---------	---------------	-----------	-----------	-----------	------------------

റ	
Δ	

	CN	AD	PSP	FTLD
Demographics			1	
Number	40	48	50	26
Age	66.0 (10.4)	69.3 (11.4)	71.2 (7.5)	65.0 (11.4)
Gender (male/female)	21/19	27/21	21/29	18/8
Years of schooling	14.8 (1.6)	13.9 (2.2)	13.6 (2.6)	14.0 (2.8)
MMSE	29.3 (1.0) [†]	21.9 (4.1)*	24.8 (5.8)*†	23.8 (6.1)*
FAB	16.7 (1.2) [†]	13.0 (3.0)*	12.0 (3.6)*	11.0 (4.8)*
CDR (0.5/1/2/3)	N/A	23/20/4/1	N/A	N/A
PSPRS	N/A	N/A	38.1 (18.2)	N/A
Blood biomarkers				
Αβ42/40	$0.093~(0.020)^{\dagger}$	0.067 (0.020) †	0.096 (0.048) †	0.089 (0.022) [†]
N-p-tau181 (pg/mL)	1.82 (0.79) [†]	4.07 (1.52)*	2.27 (1.06) [†]	2.25 (1.25) [†]
mid-p-tau181 (pg/mL)	0.83 (0.65) [†]	2.30 (1.31)*	1.56 (0.91)*	0.96 (0.63) [†]
NfL (pg/mL)	19.5 (12.5) †‡	33.2 (21.3) *‡	58.3 (39.7) *†	51.8 (39.3)*

3 CN, cognitively normal; AD, Alzheimer's disease; PSP, progressive supranuclear palsy;

4 FTLD, frontotemporal degeneration; MMSE, Mini-Mental State Examination; FAB,

5 Frontal Assessment Battery; CDR, Clinical Dementia Rating scale; PSPRS, progressive

6 supranuclear palsy rating scale; N/A, not applicable; A β , amyloid beta; N-p-tau181,

7 phosphorylated tau181 measured using the commercial kit directed to the C-terminally

8 truncated N-terminal fragment of p-tau (Simoa pTau-181 V2.1 Assay, Quanterix);

9 mid-p-tau181, phosphorylated tau181 measured using the originally developed

10 immunoassay directed to both the N- and C-terminally truncated p-tau181 fragments;

11 NfL, neurofilament light chain.

12 Values are presented as mean \pm standard deviation.

^{*}, Significant difference between CN, [†], between AD, [‡], between PSP, P < 0.05

14 (corrected by Dunn's multiple comparisons)

- 1 Table 2. Performance of mid-p-tau181 in discriminating tau PET status determined
- 2 using three different methods of evaluating brain tau burden on tau PET in the

3 cognitively normal and AD continuum subjects

4

	Sensitivity	Specificity	Cutoff value	AUC
	(%)	(%)	(pg/mL)	
Braak staging	62.8	92.5	1.76	0.859
Temporal meta SUVR	71.8	88.6	1.69	0.855
AD tau score	70.5	88.1	1.62	0.870

5

6 All parameters were estimated from receiver operating characteristic curve analyses. We

set each cutoff value according to Youden index obtained in the respective receiveroperating characteristic analyses.

9 SUVR, standardized uptake value ratio; AUC, area under the receiver operating 10 characteristic curve.

11

1 Figure legends

 $\mathbf{2}$

Figure 1. Correlations between plasma mid-p-tau levels and tau PET results in the subjects with AD continuum.

- 5 (A) The correlation between plasma mid-p-tau181 levels and ¹⁸F-florzorotau tau PET is
- depicted through its topographical representation (p < 0.05, family-wise error
 corrected).
- 8 (B, C) The correlation between plasma mid-p-tau181 levels and tau PET tracer
- 9 accumulation in each ROI is portrayed via scatter plots. Pearson's correlation analysis
- 10 was employed to calculate the r and p values. Statistical significance was established at
- 11 p < 0.0125, corrected for multiple comparisons using the Bonferroni method based on
- 12 the number of ROIs. Regression analysis, indicated by a straight or curved line, depicts
- 13 the preferred model, with its goodness of fit quantified using the R^2 value.
- 14 SUVR, standardized uptake value ratio; AD tau score, a machine learning-based
- 15 measure indicating AD-related features in tau PET images.
- 16 Mid-p-tau181, phosphorylated tau181 measured using the originally developed
- 17 immunoassay directed to both N- and C-terminally truncated p-tau181 fragments.
- 18

19 Figure 2 Correlation between plasma N-p-tau levels measured using a conventional

20 p-tau assay and tau PET results in the subjects with AD continuum.

- 21 (A) The correlation between plasma N-p-tau181 levels and tau PET results is
- demonstrated through its topographical representation (p < 0.05, uncorrected).
- 23 (B, C) The correlation between plasma N-p-tau181 levels and tau PET tracer
- 24 accumulation in each ROI is depicted via scatter plots. Pearson's correlation analysis
- 25 was utilized to calculate the r and p values. The preferred model, indicated by regression
- 26 analysis, is depicted by a straight or curved line, with its goodness of fit quantified using 27 the R^2 value.
- SUVR, standardized uptake value ratio; AD tau score, a machine learning-based measure indicating AD-related features in tau PET images.
- N-p-tau181, phosphorylated tau181 measured using the Simoa pTau-181 V2.1 Assay kit
- 31 (Quanterix).
- 32
- **Figure 3. Scatter plots and ROC curves of the mid-p-tau181 showing its ability to**
- 34 discriminate between tau PET statuses determined by three different approaches
- 35 in the cognitively normal and AD continuum subjects.

- 1 Scatterplots (A) and ROC curves (B) illustrating the relationship between mid-p-tau181
- 2 levels and positive/negative tau PET results as determined by three different methods. In
- 3 the scatterplot, CN subjects are represented in purple, whereas AD continuum patients
- 4 are depicted in blue. The dotted line represents the mid-p-tau181 cutoff calculated based
- 5 on each approach. p < 0.0001 (****), as assessed by Mann–Whitney U test.
- 6

Figure 4. Correlations between plasma mid-p-tau and N-p-tau levels and MRI structural images in the subjects with AD continuum.


- 9 (A) The correlation between p-tau181 measured using the mid-p-tau181 or N-p-tau
- 10 assay and brain atrophy is depicted through its topographical representation (p < 0.05,
- 11 uncorrected).
- 12 (B) The correlation between plasma mid-p-tau181 and N-p-tau levels measured using
- 13 each assay and the thinning of the AD cortical signature is demonstrated via scatter
- 14 plots. Pearson's correlation analysis was utilized to calculate.
- 15 N-p-tau181, phosphorylated tau181 measured using the Simoa pTau-181 V2.1 Assay kit
- 16 (Quanterix); mid-p-tau181, phosphorylated tau181 measured using the originally
- 17 developed immunoassay directed to both N- and C-terminally truncated p-tau181
- 18 fragments.
- 19


Figure 5. Comparative analyses of blood biomarkers across the clinical diagnosis groups and between the amyloid PET status.

- 22 (A) The data distribution is portrayed using scatter plots, with group differences having
- 23 been evaluated through the Kruskal–Wallis test. Statistically significant differences are
- 24 denoted as follows: p < 0.0001 (****), p = 0.0004, or 0.0010 (***), p = 0.0070 (**),
- and non-significant at p < 0.05 (ns), as determined using Dunn's multiple comparisons.
- 26 (B) ROC curves were utilized to differentiate AD from other groups determined
- according to qualitative findings of amyloid PET. The corresponding AUC values arelisted.
- 29 CN, cognitively normal; AD, Alzheimer's disease; PSP, progressive supranuclear palsy;
- ³⁰ FTLD, frontotemporal degeneration; Aβ, amyloid beta; N-p-tau181, phosphorylated
- tau181 measured with the Simoa pTau-181 V2.1 Assay kit (Quanterix); mid-p-tau181,
- 32 phosphorylated tau181 measured using the originally developed immunoassay directed
- to both N- and C-terminally truncated p-tau181 fragments; NfL, neurofilament light
- 34 chain; ROC, Receiver Operating Characteristic; AUC, area under the ROC curve.
- 35

1 Figure 6. Trajectories of the imaging and plasma A/T/N biomarkers along with the

- 2 decline in the MMSE scores.
- 3 Trajectories of the changes in imaging (A) and blood-based (B) A/T/N biomarkers with
- 4 the decline in MMSE scores. The relationship between MMSE scores of the CN and AD
- 5 continuum subjects and the z-scores of each biomarker is presented as a regression line
- 6 that is either straight or sigmoidal, with the best fitting model being selected. The
- 7 biomarkers were distinguished using red, green, and blue for both imaging and
- 8 blood-based biomarkers, whereas N-p-tau181 was presented separately in purple. The
- 9 dotted line indicates z-score = 1.





2.0

2.5

0.5

1.0

1.5

SUVR (Braak V/VI)


2.0


2.5


0.5 2.0 1.0 1.5 SUVR (Braak I/II)


2.5

0 -1.5 0.5 1.0 SUVR (Braak III/IV)











(B) Amyloid (+) vs Amyloid (-)



- Αβ42/Αβ40
- N-p-tau181
- Mid-p-tau181

— NfL

	AUC values
Αβ42/40	0.714
N-p-tau181	0.905
Mid-p-tau181	0.844
NfL	0.641



(A)